Pathways in pulmonary arterial hypertension: The future is here

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 321-327

  Sitbon, Olivier ^a   Morrell, Nicholas W ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Endothelin; Nitric oxide; Prostacyclin; Pulmonary arterial hypertension; Survival

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; CYCLOSPORIN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IMATINIB; KETOCONAZOLE; MACITENTAN; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE V; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTAGLANDIN RECEPTOR; PROSTANOID; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TERGURIDE; THROMBOXANE A2; TREPROSTINIL; WARFARIN;

ADD ON THERAPY; ANEMIA; ANGIOGENESIS; CHRONIC MYELOID LEUKEMIA; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXERCISE TOLERANCE; FIBROSING ALVEOLITIS; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LIVER DISEASE; LUNG FIBROSIS; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOGENESIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SUBDURAL HEMATOMA; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VOMITING;

ACETAMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; ENDOTHELIN-1; EPOPROSTENOL; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; LISURIDE; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRAZINES; PYRAZOLES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SEROTONIN ANTAGONISTS; SULFONAMIDES;

EID: 84870755485     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004812     Document Type: Review

References (60)

1. Galie' N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial metaanalyses. Eur Heart J 2010; 31: 2080-2086.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
3. Dupuis J. Endothelin: setting the scene in PAH. Eur Respir Rev 2007; 16: 3-7.
4. Galie' N, Manes A, Branzi A, et al. The new clinical trials on pharmacologic treatment in pulmonary arterial hypertension. Eur J Clin Investig 1996; 26: A48.
5. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
6. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237.
7. Iglarz M, Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond) 2010; 119: 453-463.
8. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur J Respir 2008; 31: 407-415.
9. Teerlink JR, Carteaux JP, Sprecher U, et al. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 1995; 268: H432-H440.
10. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-854.
11. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-16068.
12. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
13. Frelin C, Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 1994; 28: 1613-1622.
14. Desmarets J, Gresser O, Guedin D, et al. Interaction of endothelin-1 with cloned bovine ETA receptors: biochemical parameters and functional consequences. Biochemistry 1996; 35: 14868-14875.
15. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327: 736-745.
16. Iglarz M, Landskroner K, Rey M, et al. Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: A6445.
17. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11: 1066-1073.
18. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-231.
19. Raghu G, Million-Rousseau R, Morganti A, et al. Efficacy and safety of macitentan in idiopathic pulmonary fibrosis: results of a prospective, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2012; 185: A3631.
20. Bruderer S, Aänismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissuetargeting dual endothelin receptor antagonist. AAPS J 2011; 14: 68-78.
21. Sidharta PN, Atsmon J, Dingemanse J. Investigation of the effect of ketoconazole on the pharmacokinetics of macitentan in healthy male subjects. Br J Clin Pharmacol 2010; 70: 730-731.
22. Sidharta PN, van Giersbergen PL, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67: 977-984.
23. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
24. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
25. Arnold WP, Mittal CK, Katsuki S, et al. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-3207.
26. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62: 1759-1764.
27. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702.
28. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522.
29. Galie' N, Ghofrani HA, Torbicki A, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
30. Galie' N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
31. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003; 78: 1207-1213.
32. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
33. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36: 792-799.
34. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010; 104: 9-21.
35. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
36. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
37. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000; 1483: 285-293.
38. Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007; 322: 1181-1188.
39. Farber HW, Miller DP, Beery FS, et al. Use of parenteral prostanoids at time of death in patients with pulmonary arterial hypertension in REVEAL. Chest 2011; 140: 903A.
40. Rubin LJ, Parikh K, Pulido T, et al. FREEDOM-M: efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension. Chest 2011; 140: 1044A.
41. United Therapeutics. FREEDOM-C trial of oral treprostinil in pulmonary arterial hypertension fails to meet primary endpoint. November 17, 2008. http://ir.unither.com/releasedetail.cfm? ReleaseID5347887 Date last accessed: August 1, 2012.
42. United Therapeutics. FREEDOM-M trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint. June 6, 2011. http://ir.unither.com/releasedetail.cfm?ReleaseID5582786 Date last accessed: August 1, 2012.
43. Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002; 62: 107-133.
44. Rich J, Hoeper MM. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer? Int J Clin Pract Suppl 2009; 161: 17-18.
45. Ikeda D, Tsujino I, Sakaue S, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007; 71: 1829-1831.
46. Oudiz RJ, Benza RL, Delcroix M, et al. Long-term follow-up in PAH patients dosed with beraprost sodium modified release (BPSMR) tablets, an oral twice daily prostacyclin analogue. Am J Respir Crit Care Med 2011; 183: A5905.
47. Armstrong DJ, Benza RL, Delcroix M, et al. Clinical pharmacology and safety of beraprost sodium modified release (BPS-MR), an oral twice daily prostacyclin analogue-a phase II study. Am J Respir Crit Care Med 2010; 181: A3360.
48. Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 2010; 335: 249-255.
49. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012; 40: 874-880.
50. Freyhaus H, Dumitrescu D, Berghausen E, et al. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 2012; 21: 119-134.
51. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005; 115: 2691-2694.
52. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
53. Redner RL. Why doesn't imatinib cure chronic myeloid leukemia? Oncologist 2010; 15: 182-186.
54. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
55. Patterson KC, Weissmann A, Ahmadi T, et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153.
56. Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
57. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-1177.
58. Hoeper MM, Barst R, Bourge R, et al. Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: the IMPRES Study. Chest 2011; 140: 1045A.
59. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
60. Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-ofconcept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med 2012; 185: A2496.